Summary of present design of discrete choice experiments for patient preferences in lung cancer based on the ISPOR...

Lung cancer is one of the most common cancers worldwide and is associated with a high mortality rate. Addressing unmet medical needs in lung cancer treatments from the perspective of patient preferences has become an important research focus. Discrete Choice Experiments (DCEs) are commonly used to assess patient preferences, therefore it is essential to interpret their analysis methods and results appropriately. This scoping review was intended to examine DCE studies on patient preferences for lung cancer treatments published after the release of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) ESTIMATE checklist in 2016, and to identify challenges in applying the checklist.

Literatures meeting the eligibility criteria for DCE studies on patient preferences for lung cancer treatments were identified through PubMed and Cochrane Library searches and reviewed independently by two reviewers according to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) Scoping Review extension. All literatures were reviewed and assessed using the ISPOR ESTIMATE checklist.

Twelve DCE studies published between January 2017 and June 2022 were identified. All studies used efficacy and side effects as attributes while less than half studies used cost. Our assessment revealed that all studies completed the checklists of Interpretation, Method, and Assumptions domains. However, the checklists in Evaluation, Stochastic, and Trade-offs domains were not completed in 83.3%, 41.7%, and 33.3% of the 12 studies, respectively. This suggests that further consideration is needed to ensure the appropriateness of the statistical analysis and interpretation of the results of the DCE studies for lung cancer treatments.

Our scoping review using the ISPOR ESTIMATE checklists found that the consideration points remained the focus of Evaluation, Stochastic, and Trade-offs in DCE studies on patient preferences for lung cancer treatments.